Shanghai Haohai Biological Technology Co., Ltd. provided group earnings guidance for the first half ended June 30, 2019. During the first half of 2019, the Group is expected to be operate smoothly and well. Taking account of the overall industry development and the Group's actual business performance, the company expects that the Group will record revenue in the range from approximately RMB 767.00 million to RMB 800.00 million, representing a year-on-year change of about 0.0% to 4.3%; profit attributable to owners of the parent company is expected to be in the range from approximately RMB 182.00 million to RMB 200.00 million, representing a year-on-year change of about -13.9% to -5.4%; and profit attributable to owners of the parent company after deducting non-recurring profit and loss is expected to be in the range from approximately RMB 180.00 million to RMB 198.00 million, representing a year-on-year change of about -10.2% to -1.2%.